Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110194 | 0.86 | KMT2A (0.41) | KMT2AALDH1A1TSHRL3MBTL1MAPK1 | |
| SCHEMBL30716833 | 0.82 | CYP2C19 (0.42) | ALDH1A1CYP2C19 | |
| SCHEMBL245571 | 0.82 | — | — | |
| SCHEMBL19148316 | 0.82 | KMT2A (0.34) | KMT2AALDH1A1TSHRL3MBTL1MAPK1 | |
| Hydrochloric Acid SCHEMBL11173735 | 0.80 | — | — | |
| SCHEMBL23896633 | 0.80 | KMT2A (0.33) | KMT2AALDH1A1TSHRL3MBTL1MAPK1 | |
| SCHEMBL15564616 | 0.79 | KMT2A (0.41) | KMT2AALDH1A1TSHRL3MBTL1MAPK1 | |
| SCHEMBL25209238 | 0.79 | KMT2A (0.34) | KMT2AALDH1A1TSHRL3MBTL1MAPK1 | |
| SCHEMBL14212551 | 0.78 | ALDH1A1 (0.41) | KMT2AALDH1A1TSHRL3MBTL1MAPK1 | |
| SCHEMBL31601155 | 0.77 | CYP4F2 (0.34) | KMT2AALDH1A1TSHRL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097104-A1 | THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| US-7012081-B2 | Anthranyl amides and their use as medicaments | SCHERING AG (DE) | 2006-03-14 | — | — | US | disclosed |
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| CN-1429200-A | Anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2003-07-09 | — | — | CN | disclosed |
| EP-1280762-A2 | ANTHRANYL AMIDES AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085671-A2 | ANTHRANYL AMIDES AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | AADAC, ANTXR2, VEGFA | KMT2A 1670/4885ALDH1A1 1532/4885TSHR 3635/4885 |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | AADAC, ANTXR2, VEGFA | KMT2A 1807/4885ALDH1A1 1386/4885TSHR 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.